Bicara Therapeutics BCAX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's cash & equivalents?
- Bicara Therapeutics (BCAX) reported cash & equivalents of $323.46M in Q1 2026.
- How has Bicara Therapeutics's cash & equivalents changed year-over-year?
- Bicara Therapeutics's cash & equivalents decreased by 30.0% year-over-year, from $462.07M to $323.46M.
- What is the long-term trend for Bicara Therapeutics's cash & equivalents?
- Over 3 years (2022 to 2025), Bicara Therapeutics's cash & equivalents has grown at a 185.4% compound annual growth rate (CAGR), from $4.16M to $96.69M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.